Fig. 1From: Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusClinical course over time, including treatments, diagnostic procedures and timing of disease progressionBack to article page